Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer

被引:131
作者
Nowak-Sliwinska, Patrycja [1 ,2 ,3 ]
Scapozza, Leonardo [1 ,2 ]
Ruiz i Altaba, Ariel [4 ]
机构
[1] Univ Geneva, Sch Pharmaceut Sci, Geneva, Switzerland
[2] Univ Lausanne, Geneva, Switzerland
[3] Univ Geneva, Translat Res Ctr Oncohaematol, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
[4] Univ Geneva, Fac Med, Dept Genet Med & Dev, Rue Michel Servet 1, CH-1211 Geneva 4, Switzerland
来源
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2019年 / 1871卷 / 02期
基金
欧洲研究理事会;
关键词
Repurposing in oncology; Colorectal cancer; Drug repositioning; Mechanism of action; Signaling pathways; On/off-target effects; Polypharmacology; Side effects; Omics; Phenotypes; Computational approaches; GENOME-WIDE ASSOCIATION; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; MAJOR DEPRESSIVE DISORDER; TYROSINE KINASE INHIBITOR; ABERRANT CRYPT FOCI; COLON-CANCER; DOUBLE-BLIND; RANDOMIZED-TRIAL; ASPIRIN USE; PHASE-II;
D O I
10.1016/j.bbcan.2019.04.005
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The strategy of using existing drugs originally developed for one disease to treat other indications has found success across medical fields. Such drug repurposing promises faster access of drugs to patients while reducing costs in the long and difficult process of drug development. However, the number of existing drugs and diseases, together with the heterogeneity of patients and diseases, notably including cancers, can make repurposing time consuming and inefficient. The key question we address is how to efficiently repurpose an existing drug to treat a given indication. As drug efficacy remains the main bottleneck for overall success, we discuss the need for machine-learning computational methods in combination with specific phenotypic studies along with mechanistic studies, chemical genetics and omics assays to successfully predict disease-drug pairs. Such a pipeline could be particularly important to cancer patients who face heterogeneous, recurrent and metastatic disease and need fast and personalized treatments. Here we focus on drug repurposing for colorectal cancer and describe selected therapeutics already repositioned for its prevention and/or treatment as well as potential candidates. We consider this review as a selective compilation of approaches and methodologies, and argue how, taken together, they could bring drug repurposing to the next level.
引用
收藏
页码:434 / 454
页数:21
相关论文
共 238 条
[1]   CIMETIDINE PRESERVES NONSPECIFIC IMMUNE FUNCTION AFTER COLONIC RESECTION FOR CANCER [J].
ADAMS, WJ ;
MORRIS, DL ;
ROSS, WB ;
LUBOWSKI, DZ ;
KING, DW ;
PETERS, L .
AUSTRALIAN AND NEW ZEALAND JOURNAL OF SURGERY, 1994, 64 (12) :847-852
[2]   Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials [J].
Algra, Annemijn M. ;
Rothwell, Peter M. .
LANCET ONCOLOGY, 2012, 13 (05) :518-527
[3]   NCATS launches drug repurposing program [J].
Allison, Malorye .
NATURE BIOTECHNOLOGY, 2012, 30 (07) :571-572
[4]  
American Medical Association, 2004, 2 AM MED ASS COUNC S
[5]   Dosing frequency of aspirin and prevention of heart attacks and strokes [J].
Amory, John K. ;
Amory, David W. .
AMERICAN JOURNAL OF MEDICINE, 2007, 120 (04) :E5-E5
[6]   Literature mining, ontologies and information visualization for drug repurposing [J].
Andronis, Christos ;
Sharma, Anuj ;
Virvilis, Vassilis ;
Deftereos, Spyros ;
Persidis, Aris .
BRIEFINGS IN BIOINFORMATICS, 2011, 12 (04) :357-368
[7]   Protein Adducts As Prospective Biomarkers of Nevirapine Toxicity [J].
Antunes, Alexandra M. M. ;
Godinho, Ana L. A. ;
Martins, Ines L. ;
Oliveira, M. Conceicao ;
Gomes, Ricardo A. ;
Coelho, Ana V. ;
Beland, Frederick A. ;
Marques, M. Matilde .
CHEMICAL RESEARCH IN TOXICOLOGY, 2010, 23 (11) :1714-1725
[8]  
Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
[9]   Drug repositioning: Identifying and developing new uses for existing drugs [J].
Ashburn, TT ;
Thor, KB .
NATURE REVIEWS DRUG DISCOVERY, 2004, 3 (08) :673-683
[10]  
Bagnoli JW, 2019, METHODS MOL BIOL, V1956, P305, DOI 10.1007/978-1-4939-9151-8_14